Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from a cheap steroid.

Gilead gives price tag to first coronavirus drug Remdesivir at $2,340

Gilead Sciences Inc's antiviral drug remdesivir prevented lung disease in macaque monkeys infected with the new coronavirus, according to a study published in the journal Nature on Tuesday.

Gilead's remdesivir prevents lung damage in COVID-19 study on monkeys

Gilead is a company that makes Remdesivir, another drug, that experts say holds promise against coronavirus. In the US, Remdesivir is undergoing clinical trials.

Gilead starts clinical trials of Remdesivir with US lawmakers curious about selling price

American pharmaceutical company Gilead Sciences reported today that its experimental coronavirus therapy remdesivir helped improve symptoms in COVID-19 patients when it was administered early than those who were treated late.

Remdesivir, tested against coronavirus showed positive results: US company Gilead Sciences

gilead-sciences

Gilead Sciences, News on Gilead Sciences, stories on Gilead Sciences, articles on Gilead Sciences, Gilead Sciences stories at Wion, Gilead Sciences news, Gilead Sciences latest news

gilead sciences

Gilead gives price tag to first coronavirus drug Remdesivir at $2,340

Gilead's remdesivir prevents lung damage in COVID-19 study on monkeys

Gilead starts clinical trials of Remdesivir with US lawmakers curious about selling price

Remdesivir, tested against coronavirus showed positive results: US company Gilead Sciences